Summary:
AMSBIO introduces a new range of ready-to-use hiPSC-derived cells, designed to streamline research by eliminating in-house differentiation and reducing preparation time.
Takeaways:
- Fully differentiated and high-purity hiPSC-derived cells save time by eliminating the need for in-house preparation.
- Functionally validated cells allow direct application to assays, benefiting CROs and life science labs.
- Consistent batch-to-batch quality ensures reliable experimental outcomes for drug discovery, disease modeling, and toxicity screening.
AMSBIO announces a new range of ready-to-use human induced pluripotent stem cell (hiPSC) -derived cardiomyocytes, hepatocytes, and neurons. Supplied fully differentiated and available in high-purity formats, these ready-to-use cells help accelerate research by streamlining lab workflows, eliminating the need for in-house differentiation and minimizing preparation time.
Provided as functionally validated cells, researchers do not need to spend time on in-house validation and can instead apply them directly to their assays without additional steps. This is a major advantage for contract research organizations (CROs) and life science labs who can save time and money on optimization work.
Outstanding batch-to-batch consistency ensures that AMSBIO’s iPSC-derived cells deliver reliable experimental outcomes every time, according to the company. These hiPSC-derived cells provide a reliable and physiologically relevant alternative to primary cells and animal models, offering researchers a consistent and scalable source of cells for drug discovery, disease modelling, and toxicity screening.
Featured Image: Representative images (left to right) of Neuronal Cells, Hepatocytes, and Cardiomyocytes. Left: Image of a group of brain cells with Neuronal cells stained in green, Astrocytes in red, and Microglia Cells in blue; Centre: Hepatocytes stained with H&E; Right: Cultured cardiac cells stained for calponin in green, N-cadherin in red, and DNA in blue. Image: AMSBIO
